课题基金 / 基金详情

Host-directed drug development for tuberculosis

Host-directed drug development for tuberculosis
宿主导向的结核病药物开发
批准号：
473323
负责人：
Sun Jim
金额：
$54.64万
依托单位：
University of Ottawa
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-09-01 至 2027-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=473323&lang=en
关键词：
Autophagy Host Response To Tuberculosis Host-Directed Drug Discovery Host-Directed Therapy Innate Immune Response Macrophage Antibacterial Pathways Metal Dependent Phosphatases Mycobacterium Tuberculosis Ppm1a Tuberculosis

项目摘要

项目成果

Sun Jim的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Tuberculosis (TB) is a contagious respiratory disease of the lung caused by inhaling the bacterium Mycobacterium tuberculosis (Mtb), and until the 2020 coronavirus pandemic, was the leading causes of infectious disease-related deaths worldwide. Inhaled Mt
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular basis of PPM1A controlled macrophage apoptosis in tuberculosis
  • 批准号：
    388433
  • 项目类别：
    Operating Grants
  • 资助金额：
    $60.75万
  • 财政年份：
    2018
  • 负责人：
    Sun Jim
  • 依托单位：
    University of Ottawa